FRONTIER BIOTECHNOLOGIES
Manufacturing · China · 201-500 Employees
View Company Info for Free
Overview
Headquarters
Shiqiaopukeyuansi St, Chongqing, Chongqi...Phone Number
+86 2368692268Website
www.frontierbiotech.comRevenue
$17 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About FRONTIER BIOTECHNOLOGIES
Frontier is an innovation-driven biopharmaceutical company. Through more than a decade of committed effort, Frontier Biotech has built an extraordinary team with international vision and deep expertise in new drug development and established a fully integrated state-of-the-art long-acting peptide new drug innovation platform with global intellectual properties. In addition to the launch of Aikening®, a Category 1 product and the first long-acting HIV fusion inhibitor in the world, Frontier Biotech is advancing an array of clinical assets through our R&D pipeline. This includes multiple programs reaching Phase 1 and 2 clinical trials in China and the United States.Explore more
FRONTIER BIOTECHNOLOGIES Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is FRONTIER BIOTECHNOLOGIES your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if FRONTIER BIOTECHNOLOGIES is spiking on competitors!
Product Launch: Get notified when FRONTIER BIOTECHNOLOGIES launches new products
Congratulate Masked Content for being promoted to Masked Content at FRONTIER BIOTECHNOLOGIES
Earning: See what the market has to say on FRONTIER BIOTECHNOLOGIES recently announced quarterly report
Check if FRONTIER BIOTECHNOLOGIES has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Click to see if FRONTIER BIOTECHNOLOGIES had a recent Job posting/layoffs
Funding: Get notified immidiatlly once FRONTIER BIOTECHNOLOGIES has new funding data
FRONTIER BIOTECHNOLOGIES, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Reach out to Masked Content who joined FRONTIER BIOTECHNOLOGIES as Masked Content
Find 3 more new buyers
Company Profile Activity
Activity Insights
FRONTIER BIOTECHNOLOGIES is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
FRONTIER BIOTECHNOLOGIES is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about FRONTIER BIOTECHNOLOGIES.
FRONTIER BIOTECHNOLOGIES financials insights
Gather financial insights about FRONTIER BIOTECHNOLOGIES, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2017
Series C
$43M
FRONTIER BIOTECHNOLOGIES Tech Stack
A closer look at the technologies used by FRONTIER BIOTECHNOLOGIES
See more technologies
FRONTIER BIOTECHNOLOGIES News & Media
FRONTIER BIOTECHNOLOGIES ANNOUNCES POSITIVE PHASE 1 RESULTS OF ITS FIRST CORONAVIRUS MAIN PROTEASE (MPRO) SMALL MOLECULE INHIBITOR, LAYING FOUNDATION FOR THE TREATMENT OF ACUTE AND LONG COVID
FB2001 (Bofutrelvir) is a Coronavirus Mpro inhibitor, which exhibited potent anti-SARS-CoV-2 activity in vitro and in vivo Phase 1 results show FB2001 to be generally safe and well tolerated. No significant difference was observed between Chinese and American populations. Single-agent...AFFiRiS and Frontier Biotechnologies announce license agreement for AFFITOPE®AT04, an active immunotherapy targeting PCSK9 to treat hypercholesterolemia, in Greater China
Frontier Biotechnologies obtains exclusive rights to develop and commercialize AFFITOPE® AT04 in Greater China Collaboration accelerates the global development of AFFiRiS potential first-in-class active immunotherapy with plans to bring production and clinical trials of AT04 to Greater China VIENNA, Austria, Dec. 22, 2021 (GLOBE NEWSWIRE) -- AFFiRiS AG, a clinical-stage biotechnology company developing novel disease-modifying Specific Active Immunotherapies (SAITs), today announced an exclusiveFrontier Biotechnologies' Long-acting Injectable (Aikening(R)), in a Two Drug Regimen, Proves Safe and Effective for Critically Ill Hospitalized AIDS Patients
LONDON, Oct. 27, 2021 /PRNewswire/ -- Frontier Biotechnologies today shared real-world evidence of Albuvirtide (ABT)-based two drug regimen's safety and efficacy for hospitalized AIDS patients at the European AIDS Clinical Society (EACS) Conference. Observations from a single-center,...Frontier Biotechnologies' First Long-acting Injectable (Aikening(R)), in a Two Drug Regimen for HIV, Proves Safe and Efficacious for Patients
The TALENT study (TALENT) findings, which were presented at the 11th International AIDS Society (IAS) Conference on HIV Science, showed that a two-drug regimen was as effective and safe as multi-drug therapies TALENT is the world's first phase III clinical trial of the new long-acting...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding FRONTIER BIOTECHNOLOGIES
Sign Up For FreeTo access detailed company insights
Frontier is an innovation-driven biopharmaceutical company. Through more than a decade of committed effort, Frontier Biotech has built an extraordinary team with international vision and deep expertise in new drug development and established a fully integrated state-of-the-art long-acting peptide new drug innovation platform with global intellectua... Read More
